Thrombospondin-1 type 1 repeats in a model of inflammatory bowel disease: Transcript profile and therapeutic effects

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Lopez Dee, Zenaida P ^a,c   Chittur, Sridar V ^b   Patel, Bhumi ^a   Stanton, Rebecca ^a   Wakeley, Michelle ^a   Lippert, Brittany ^a   Menaker, Anastasya ^a   Eiche, Bethany ^a   Terry, Robert ^a   Gutierrez, Linda S ^a  

^a WILKES UNIVERSITY   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c Janet Weis Children s Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN SULFATE; RECOMBINANT PROTEIN; RNA; SODIUM CHLORIDE; THROMBOSPONDIN 1; THROMBOSPONDIN STRUCTURAL REPEAT 2; THROMBOSPONDIN STRUCTURAL REPEAT 3; UNCLASSIFIED DRUG; MESSENGER RNA; TRANSCRIPTOME;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL ADHESION; CELL INFILTRATION; COLITIS; COLON MUCOSA; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; RNA HYBRIDIZATION; RNA ISOLATION; TRANSCRIPTOMICS; WILD TYPE; ANIMAL; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; ENTERITIS; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PROTEIN TERTIARY STRUCTURE; STEM CELL; UPREGULATION;

MUS;

ANIMALS; APOPTOSIS; CELL ADHESION; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; INFLAMMATORY BOWEL DISEASES; LEUKOCYTES; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN STRUCTURE, TERTIARY; REAL-TIME POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; REPETITIVE SEQUENCES, AMINO ACID; RNA, MESSENGER; STEM CELLS; THROMBOSPONDIN 1; TRANSCRIPTOME; UP-REGULATION;

EID: 84859262953     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034590     Document Type: Article

References (47)

1. Lawler J, (1986) The structural and functional properties of thrombospondin. Blood 67: 1197-1209.
2. Lawler J, Hynes RO, (1986) The structure of human thrombospondin, an adhesive glycoprotein with multiple calcium-binding sites and homologies with several different proteins. J Cell Biol 103: 1635-1648.
3. Carlson CB, Lawler J, Mosher DF, (2008) Structures of thrombospondins. Cell Mol Life Sci 65: 672-686.
4. Adams JC, Tucker RP, (2000) The thrombospondin type 1 repeat (TSR) superfamily: diverse proteins with related roles in neuronal development. Dev Dyn 218: 280-299.
5. Tucker RP, (2004) The thrombospondin type 1 repeat superfamily. Int J Biochem Cell Biol 36: 969-974.
6. Chen H, Herndon ME, Lawler J, (2000) The cell biology of thrombospondin-1. Matrix Biol 19: 597-614.
7. Simantov R, Silverstein RL, (2003) CD36: a critical anti-angiogenic receptor. Front Biosci 8: s874-882.
8. Simantov R, Febbraio M, Silverstein RL, (2005) The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. Matrix Biol 24: 27-34.
9. Short SM, Derrien A, Narsimhan RP, Lawler J, Ingber DE, et al. (2005) Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J Cell Biol 168: 643-653.
10. Miao WM, Seng WL, Duquette M, Lawler P, Laus C, et al. (2001) Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through Transforming growth factor-B-dependent and-independent mechanisms. Cancer Res 61: 7830-7839.
11. Ren B, Song K, Parangi S, Jin T, Ye M, et al. (2009) A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR. Cancer Res 69: 3856-3865.
12. Zhang X, Galardi E, Duquette M, Delic M, Lawler J, et al. (2005) Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model. Clin Cancer Res 11: 2337-2344.
13. Yee KO, Streit M, Hawighorst T, Detmar M, Lawler J, (2004) Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta. Am J Pathol 165: 541-552.
14. Haviv F, Bradley MF, Kalvin DM, Schneider AJ, Davidson DJ, et al. (2005) Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. J Med Chem 48: 2838-2846.
15. Punekar S, Zak S, Kalter VG, Dobransky L, Punekar I, et al. (2008) Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease. Pathobiology 75: 9-21.
16. Andersen CL, Jensen JL, Orntoft TF, (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64: 5245-5250.
17. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, et al. (2010) The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res 38: W214-220.
18. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, et al. (2007) Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449: 1003-1007.
19. Sato T, van Es JH, Snippert HJ, Stange DE, Vries RG, et al. (2011) Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature 469: 415-418.
20. Zhang X, Kazerounian S, Duquette M, Perruzzi C, Nagy JA, et al. (2009) Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J 23: 3368-3376.
21. Petersson J, Schreiber O, Steege A, Patzak A, Hellsten A, et al. (2007) eNOS involved in colitis-induced mucosal blood flow increase. Am J Physiol Gastrointest Liver Physiol 293: G1281-1287.
22. Isenberg JS, Martin-Manso G, Maxhimer JB, Roberts DD, (2009) Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat Rev Cancer 9: 182-194.
23. Feagins LA, (2010) Role of transforming growth factor-beta in inflammatory bowel disease and colitis-associated colon cancer. Inflamm Bowel Dis 16: 1963-1968.
24. Gove ME, Rhodes DH, Pini M, van Baal JW, Sennello JA, et al. (2009) Role of leptin receptor-induced STAT3 signaling in modulation of intestinal and hepatic inflammation in mice. J Leukoc Biol 85: 491-496.
25. Moldobaeva A, Baek A, Eldridge L, Wagner EM, (2010) Differential activity of pro-angiogenic CXC chemokines. Microvasc Res 80: 18-22.
26. Papp M, Lakatos PL, Hungarian IBDSG, Palatka K, Foldi I, et al. (2007) Haptoglobin polymorphisms are associated with Crohn's disease, disease behavior, and extraintestinal manifestations in Hungarian patients. Dig Dis Sci 52: 1279-1284.
27. Marquez L, Shen C, Cleynen I, De Hertogh G, Van Steen K, et al. (2011) Effects of haptoglobin polymorphisms and deficiency on susceptibility to inflammatory bowel disease and on severity of murine colitis. Gut.
28. Gebhardt C, Nemeth J, Angel P, Hess J, (2006) S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 72: 1622-1631.
29. Hsu K, Champaiboon C, Guenther BD, Sorenson BS, Khammanivong A, et al. (2009) ANTI-INFECTIVE PROTECTIVE PROPERTIES OF S100 CALGRANULINS. Antiinflamm Antiallergy Agents Med Chem 8: 290-305.
30. Sunahori K, Yamamura M, Yamana J, Takasugi K, Kawashima M, et al. (2006) The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis. Arthritis Res Ther 8: R69.
31. Yasui Y, Tanaka T, (2009) Protein expression analysis of inflammation-related colon carcinogenesis. J Carcinog 8: 10.
32. Ichikawa M, Williams R, Wang L, Vogl T, Srikrishna G, (2011) S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res 9: 133-148.
33. Santiago JL, Alizadeh BZ, Martinez A, Espino L, de la Calle H, et al. (2008) Study of the association between the CAPSL-IL7R locus and type 1 diabetes. Diabetologia 51: 1653-1658.
34. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, et al. (2007) Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 39: 857-864.
35. Pilka ES, Niesen FH, Lee WH, El-Hawari Y, Dunford JE, et al. (2009) Structural basis for substrate specificity in human monomeric carbonyl reductases. PLoS One 4: e7113.
36. Amsterdam A, Shezen E, Raanan C, Slilat Y, Ben-Arie A, et al. (2011) Epiregulin as a marker for the initial steps of ovarian cancer development. Int J Oncol 39: 1165-1172.
37. Migeotte I, Communi D, Parmentier M, (2006) Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses. Cytokine Growth Factor Rev 17: 501-519.
38. Sipione S, Simmen KC, Lord SJ, Motyka B, Ewen C, et al. (2006) Identification of a novel human granzyme B inhibitor secreted by cultured sertoli cells. J Immunol 177: 5051-5058.
39. Kolset SO, Tveit H, (2008) Serglycin-structure and biology. Cell Mol Life Sci 65: 1073-1085.
40. Schick BP, Gradowski JF, San Antonio JD, (2001) Synthesis, secretion, and subcellular localization of serglycin proteoglycan in human endothelial cells. Blood 97: 449-458.
41. Zernichow L, Abrink M, Hallgren J, Grujic M, Pejler G, et al. (2006) Serglycin is the major secreted proteoglycan in macrophages and has a role in the regulation of macrophage tumor necrosis factor-alpha secretion in response to lipopolysaccharide. J Biol Chem 281: 26792-26801.
42. Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, et al. (2004) Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 53: 685-693.
43. Swidsinski A, Loening-Baucke V, Herber A, (2009) Mucosal flora in Crohn's disease and ulcerative colitis- an overview. J Physiol Pharmacol 60 (Suppl 6): 61-71.
44. Hagiwara K, Kikuchi T, Endo Y, Huqun, Usui K, et al. (2003) Mouse SWAM1 and SWAM2 are antibacterial proteins composed of a single whey acidic protein motif. J Immunol 170: 1973-1979.
45. Samani AA, Yakar S, LeRoith D, Brodt P, (2007) The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights. Endocrine Reviews 28: 20-47.
46. Li Y, Geng YJ, (2010) A potential role for insulin-like growth factor signaling in induction of pluripotent stem cell formation. Growth Horm IGF Res 20: 391-398.
47. Garcia MI, Ghiani M, Lefort A, Libert F, Strollo S, et al. (2009) LGR5 deficiency deregulates Wnt signaling and leads to precocious Paneth cell differentiation in the fetal intestine. Dev Biol 331: 58-67.